News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,468 Results
Type
Article (13515)
Company Profile (102)
Press Release (245851)
Section
Business (87876)
Career Advice (460)
Deals (15320)
Drug Delivery (60)
Drug Development (36497)
Employer Resources (49)
FDA (6242)
Job Trends (6179)
News (149843)
Policy (14000)
Tag
Academia (435)
Africa (312)
Alliances (23057)
Alzheimer's disease (334)
Approvals (6232)
Arizona (35)
Artificial intelligence (46)
Asia (19676)
Australia (2536)
Bankruptcy (143)
Best Places to Work (4240)
Biosimilars (32)
Biotechnology (43)
C2C Services and Suppliers (10596)
California (671)
Canada (471)
Cancer (182)
Career advice (402)
Cell therapy (30)
China (75)
Clinical research (30136)
Collaboration (78)
Compensation (34)
Connecticut (30)
COVID-19 (742)
Data (156)
Diabetes (34)
Diagnostics (1210)
Drug pricing (53)
Earnings (31167)
Employer resources (43)
Europe (38504)
Events (36357)
Executive appointments (110)
FDA (6346)
Florida (91)
Funding (56)
Gene therapy (45)
GLP-1 (270)
Government (1256)
Healthcare (3511)
Hotbed/Location (177913)
Illinois (78)
Indiana (66)
Infectious disease (751)
Inflammatory bowel disease (44)
Interviews (57)
IPO (5786)
Job creations (2047)
Job search strategy (371)
Kansas (49)
Layoffs (165)
Legal (3400)
Lung cancer (34)
Manufacturing (62)
Maryland (106)
Massachusetts (598)
Medical device (1255)
Medtech (1257)
Mergers & acquisitions (9498)
Metabolic disorders (121)
Minnesota (40)
Neuroscience (403)
New Jersey (288)
New York (199)
NextGen Class of 2024 (1578)
Non-profit (588)
North Carolina (236)
Northern California (289)
Obesity (78)
Ohio (34)
Opinion (107)
Patents (43)
Pennsylvania (207)
People (28296)
Pharmaceutical (59)
Phase I (7834)
Phase II (12738)
Phase III (11452)
Pipeline (63)
Podcasts (37)
Policy (40)
Postmarket research (1399)
Preclinical (3137)
Press Release (25)
Radiopharmaceuticals (115)
Rare diseases (60)
Real estate (2627)
Regulatory (9734)
Research institute (562)
Resumes & cover letters (55)
South America (497)
Southern California (301)
Startups (1624)
Texas (93)
United States (2997)
Vaccines (99)
Virginia (26)
Washington State (51)
Weight loss (63)
Date
Today (43)
Last 7 days (239)
Last 30 days (1002)
Last 365 days (13205)
2024 (9823)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14887)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
259,468 Results for "alora pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Alora Pharmaceuticals, LLC , the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii ® (methylphenidate hydrochloride extended-release tablets).
December 19, 2023
·
3 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).
March 14, 2023
·
9 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals.
April 5, 2023
·
6 min read
Deals
Alora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing Facility
Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC, has acquired, through bankruptcy proceedings, substantially all of Monarch PCM, LLC’s manufacturing capabilities located in Fort Worth, TX.
January 10, 2023
·
2 min read
FDA
Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announces the FDA approval and availability of DHIVY™ for the treatment of Parkinson’s disease
Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in November 2021.
February 14, 2022
·
3 min read
Deals
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.
August 30, 2021
·
5 min read
Pharm Country
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.
June 25, 2021
·
7 min read
Press Releases
Once-daily RELEXXII® (methylphenidate hydrochloride extended-release tablet) proudly supports Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month
October 2, 2024
·
2 min read
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
1 of 25,947
Next